-
Biotech In The Earnings Spotlight: Amgen, Celgene, Gilead Sciences
Sunday, July 24, 2016 - 4:03pm | 873Read More...Three leading biotech companies will step into the earnings spotlight this week. Consensus forecasts from Wall Street analysts call for earnings growth from just two of them. And only one of them has topped estimates by double-digits in recent quarters. While the biotechnology industry has had a...
-
AstraZeneca Remains Committed To Development Of ZS-9 Despite Letter From FDA
Friday, May 27, 2016 - 7:47am | 267Read More...Shares of AstraZeneca plc (ADR) (NYSE: AZN) were trading lower by more than 1.5 percent early Friday after the company confirmed it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration relating to its New Drug Application (NDA) for sodium zirconium cyclosilicate,...
-
Big Biotech In The Earnings Spotlight
Tuesday, April 26, 2016 - 8:08am | 735Read More...The three largest biotechs are set to share their latest quarterly results this week. Wall Street analysts are looking for solid to strong growth from all three. However, expectations are lower for many other biotech and pharmaceutical companies reporting this week. The three largest public...
-
AstraZeneca Falls More Than 5% Following Q4 Print
Thursday, February 4, 2016 - 9:03am | 268Read More...Shares of AstraZeneca plc (ADR) (NYSE: AZN) were trading lower by more than 5 percent early Thursday morning after the company reported its fourth quarter results. AstraZeneca earned $0.94 per share in the fourth quarter on revenue of $6.39 billion. Wall Street analysts were expecting the...
-
Why Shares Of Valeant Pharmaceuticals Spiked
Monday, January 25, 2016 - 2:17pm | 205Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) were trading higher by more than 6 percent on Monday after the company announced the Food and Drug Administration has accepted for review the Biologics License Application (BLA) the company submitted as part of a partnership with AstraZeneca...
-
Report: AstraZeneca Eyes Acquisition Of Relypsa For $46 Per Share
Thursday, December 24, 2015 - 8:53am | 122Read More...Shares of Relypsa Inc (NASDAQ: RLYP) were trading higher by more than 2 percent at $28.60 early Thursday morning after the Daily Mail reported the company may be a potential acquisition target. The Daily Mail reported that "rumors from across the Pond" suggest that AstraZeneca plc (...
-
Highlights From ISIS Pharmaceuticals At Goldman Sachs Healthcare Conference
Thursday, June 11, 2015 - 1:36pm | 541Read More...ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) presented at Goldman Sachs' annual Global Healthcare Conference on Wednesday. VP of Corporate Communications and Investor Relations D. Wade Walke discussed the drug maker's advanced technology, business model, and current pipeline. Antisense...
-
Amgen, AstraZeneca End Development Pact; Shares Sink
Tuesday, May 26, 2015 - 8:56pm | 331Read More...Amgen, Inc. (NASDAQ: AMGN) shares lost about 2.8 percent Tuesday on fallout from the termination of a three-year-old development pact with AstraZeneca plc (NYSE: AZN). Amgen closed at $159.02, off $4.57; AstraZeneca declined 2.5 percent to $67.68. Amgen said late Friday that it would end a co...
-
Report: Pfizer 'Unlikely' To Pursue Acquisition Of AstraZeneca
Friday, November 14, 2014 - 10:38am | 288Read More...Due to British takeover rules and regulations, Pfizer Inc. (NYSE: PFE) is not permitted to present a fresh offer to acquire AstraZeneca plc (ADR) (NYSE: AZN) until November 26. Reuters reported on Friday that after several unsuccessful attempts to take over British based AstraZeneca, Pfizer is...
-
Markets Rally On Better Than Expected GDP; Dow Has Best Close In More Than A Month
Thursday, October 30, 2014 - 5:09pm | 1851Read More...U.S. stocks rose on Thursday after government data showed the U.S. economy grew 3.5 percent in the third quarter, better than the 3.0 percent expected. Investors brushed off a poor reading on the number of Americans filing for jobless benefits, which rose last week in favor of GDP data; this...
-
Deutsche Bank Says Pfizer Has A Strong Financial Position And Attractive Pipeline
Wednesday, August 27, 2014 - 11:25am | 400Read More...Gregg Gilbert of Deutsche Bank initiated coverage of Pfizer (NYSE: PFE) on Wednesday with a Buy rating and $34 price target. “While Pfizer continues to face headwinds to top-line growth and has a less obviously compelling pipeline relative to some of its peers, we like the company's...
-
Markets Continue To Rally Ahead Of Yellen's Speech At Jackson Hole
Thursday, August 21, 2014 - 5:16pm | 2993Read More...U.S. stocks rose as the S&P 500 toppled to a new all-time high of 1,994.76 while the Dow rose above the 17,000 mark following positive economic reports. Speaking from Jackson Hole, San Francisco's Federal Reserve President John Williams stated that raising the benchmark interest rate...
-
Stocks Mixed Despite Better Than Expected GDP
Wednesday, July 30, 2014 - 4:43pm | 2929Read More...U.S. stocks were mixed as the Fed continued to wind down its monthly asset purchase program by another $10 billion. The Fed noted that the economy rebounded in the second quarter despite significant under-utilization remaining in the labor market. As such, the Fed noted, it will maintain a...
-
5 British Blue Chips For Your Portfolio
Friday, July 11, 2014 - 9:20am | 458Read More...Investors should naturally be thinking risk management and protecting gains in this record bull market for the Dow Jones Industrial Average (NYSE: DIA) and the Standard & Poor's 500 Index (NYSE: SPY). An effective way to accomplish this is by diversifying holdings with British blue...
-
Dow Trades Above 17,000 While S&P 500 Inches Closer To 2,000
Thursday, July 3, 2014 - 1:20pm | 1238Read More...U.S. stocks rose ahead of the long weekend after the economy added a better-than-expected 288,000 jobs in June. The unemployment rate also dipped to 6.1 percent. The Fed's Janet Yellen confirmed its views that ti will not raise its interest rates on Wednesday at an International Monetary...
